First, bioinformatics analysis revealed that the expression of the NR2F1-AS1/miR-190a/PHLDB2 axis varied considerably between carcinoma in situ and advanced GC, with a significant correlation between the expression of EMT-related markers. The gene discussed is PHLDB2; the disease is in situ carcinoma.